Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internat…
Biotechnology
US, Novato [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Ultragenyx Pharmaceutical Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2016 | -3.9600 | -6.142 | 0 | 0.25 | -145 | -236 | -146 | -234 | -147 | -238 | 33 | 0.22 |
| 2017 | -6.2100 | -7.278 | 0.13 | 0.61 | -245 | -309 | -248 | -327 | -248 | -337 | 64 | 0.53 |
| 2018 | -7.1200 | -4.172 | 2 | 49 | -302 | -115 | -328 | -69 | -328 | -777 | 99 | 42 |
| 2019 | -3.9700 | -6.938 | 51 | 100 | -197 | -379 | -541 | -367 | -371 | -400 | 127 | 87 |
| 2020 | -7.1200 | -3.794 | 103 | 250 | -402 | -176 | -411 | -101 | -424 | -515 | 161 | 216 |
| 2021 | -3.0700 | -6.254 | 271 | 351 | -186 | -396 | -322 | -355 | -330 | -344 | 182 | 198 |
| 2022 | -6.7000 | -9.922 | 351 | 361 | -454 | -413 | -381 | -375 | -381 | -399 | 219 | 215 |
| 2023 | -10.1200 | -8.372 | 363 | 428 | -707 | -585 | -639 | -431 | -648 | -456 | 278 | 244 |
| 2024 | -8.2500 | -6.400 | 434 | 536 | -606 | -470 | -516 | -536 | -569 | -536 | 309 | 465 |
| 2025 | - | -5.277 | - | 628 | - | -393 | - | -628 | - | -628 | - | 544 |
| 2026 | - | -3.251 | - | 840 | - | 2.F10X/td> | - | 2.F101/td> | - | 2.F101 | - | 2.F101 |
| 2027 | - | -0.871 | - | 1,165 | - | 1.F11X/td> | - | 1.F111/td> | - | 1.F111 | - | 1.F111 |
| 2028 | - | 3.173 | - | 1,768 | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
Overweight
Prev. Grade
Overweight
Nov. 6, 2024
Overweight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-99.087% $45.60 · MISS
Nov. 6, 2024Price Then
$52.18
Price Target
$91.62
Price Now
$46.02